We discuss preclinical breakthroughs that have led up to our current understanding of IDH in the pathogenesis of IDH-mutant glioma, progress in the development of IDH inhibitors, and studies evaluating the use, safety, and efficacy of various IDH inhibitors. This evidence concerns the gene IDH1 and central nervous system cancer.